Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Accounts Payables: 2022-2024

Historic Accounts Payables for Abivax (ABVX) over the last 3 years, with Dec 2024 value amounting to $46.8 million.

  • Abivax's Accounts Payables rose 90.10% to $65.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $65.1 million, marking a year-over-year increase of 90.10%. This contributed to the annual value of $46.8 million for FY2024, which is 7.83% down from last year.
  • Latest data reveals that Abivax reported Accounts Payables of $46.8 million as of FY2024, which was down 7.83% from $50.8 million recorded in FY2023.
  • Abivax's Accounts Payables' 5-year high stood at $50.8 million during FY2023, with a 5-year trough of $16.3 million in FY2022.
  • For the 3-year period, Abivax's Accounts Payables averaged around $38.0 million, with its median value being $46.8 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 211.51% in 2023, then fell by 7.83% in 2024.
  • Yearly analysis of 3 years shows Abivax's Accounts Payables stood at $16.3 million in 2022, then soared by 211.51% to $50.8 million in 2023, then fell by 7.83% to $46.8 million in 2024.